Arthneeti
All Q4 FY26 results →
RB

Rajputana Bio.

Q4 FY26

Rajputana Bio. Q4 FY26 investor presentation: Revenue & Margins

Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹205
Market cap₹140 Cr
P/E15.5
Updated16 Oct 2026
Read4 min read

Based on Rajputana Bio.'s Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

For H2 FY26 (Oct-Mar 2025-26): - Revenue from Operations: ₹6,267.05 lakhs vs. EBITDA (H2 FY26): ₹1,486 lakhs (up 9.6% YoY) - Operating Margin (H2 FY26): 23.1% (up 1.7% YoY) - Profit After Tax (PAT) (H2 FY26): ₹446 lakhs (up 341% YoY) - Explicit Margin Outlook: The presentation highlights targeted revenue growth driven by biodiesel and CBG segments with improved operating efficiencies, indicating a positive margin expansion trajectory.

From Rajputana Bio.'s Q4 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

  • For H2 FY26 (Oct-Mar 2025-26):
  • Revenue from Operations: ₹6,267.05 lakhs vs. ₹2,278.10 lakhs in H2 FY25, ~175% YoY increase.
  • Total Income: ₹6,321.29 lakhs vs. ₹2,294.74 lakhs in H2 FY25.
  • Profit After Tax (PAT): ₹446.12 lakhs vs. ₹101.17 lakhs in H2 FY25.
  • EPS: 5.52 vs. 1.42 in H2 FY25.
  • Annual FY26 vs. FY25:
  • Revenue from Operations: ₹12,202.92 lakhs vs. ₹6,731.31 lakhs, ~81% YoY growth.
  • PAT: ₹1,051.91 lakhs vs. ₹591.99 lakhs.

2 more points from Rajputana Bio.'s call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Rajputana Bio. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Expansion into Compressed BioGas (CBG) with Government approval for two CBG units in Ajmer and Nagaur, Rajasthan (page 9).
  • Rajputana Agro LLP formed in March 2026 to supply biomass feedstock, supporting captive supply chain for CBG plants at Ajmer and Nagaur (page 12).
  • Technical upgradation at Phulera Plant (timeline indicates 2019) to enhance capacity and quality (page 11).
  • Existing biodiesel manufacturing capacity: 170 KLPD across two plants (Phulera - 90 KLPD, Meerut - 80 KLPD) with ongoing production ramp-up (pages 6, 22).
  • Capital Work in Progress stands at ₹8.36 crores (₹836.39 lakhs) as of FY26, indicating active investment in assets (page 18).

2 more points from Rajputana Bio.'s call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

See what Rajputana Bio. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report specific order book values, order inflows, or pending orders with exact figures. However, it does mention: - **Large-scale orders from Government PSUs**: Highlighted as a key achievement validating Rajputana Biodiesel’s strategic vision. - **OMC Contracts**: Supply contracts with India’s major Oil Marketing Companies (HPCL, BPCL, IOCL) ensuring consistent revenue visibility and volume offtake certainty.

2 more points from Rajputana Bio.'s call on order book

Pro opens every point from 15K+ earnings calls

Continue your research

What Rajputana Bio.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Indian Phosphate (Q4 FY26)

    H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In

  • Vishnu Chemicals Ltd (Q4 FY26)

    Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4

  • SPEB Adhesives Ltd (Q4 FY26)

    The company plans to double its manufacturing capacity, currently at about 80% utilization, with new capacity ramp-up phased over time. Key concall takeaways…

  • Chemfab Alka. (Q4 FY26)

    Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key concall takeaways from Chemfab Alkalis Ltd's Q4 FY26 earnings call — and how it…

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Rajputana Bio. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Rajputana Bio. Q4 FY26 results?

For H2 FY26 (Oct-Mar 2025-26): - Revenue from Operations: ₹6,267.05 lakhs vs. EBITDA (H2 FY26): ₹1,486 lakhs (up 9.6% YoY) - Operating Margin (H2 FY26): 23.1% (up 1.7% YoY) - Profit After Tax (PAT) (H2 FY26): ₹446 lakhs (up 341% YoY) - Explicit Margin Outlook: The presentation highlights targeted revenue growth driven by biodiesel and CBG segments with improved operating efficiencies, indicating a positive margin expansion trajectory.

What is Rajputana Bio. share price analysis?

Rajputana Bio. currently shows a neutral. The stock trades at a P/E of 15.5 with a market cap of ₹140 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rajputana Bio. planning capital expenditure?

Expansion into Compressed BioGas (CBG) with Government approval for two CBG units in Ajmer and Nagaur, Rajasthan (page 9).

Keep Rajputana Bio. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.